An interventional study of Workplace convergence dialogue and Care Manager in Depressive Disorder and Anxiety Disorders, sponsored by Göteborg University. Active, not recruiting at 1 site in Sweden. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2025-04-11.
Sponsored by Göteborg University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Depressive Disorder with a site in Sweden — 3 open to participants now, 5 under way, none of them phase 3. Depressive Disorder · Sweden.
Among the 14 studies in Depressive Disorder with a site in Sweden, this one is the 3rd largest by enrollment, is the only one that started in 2017, is one of 7 with no phase, and was the 6th registered.
855 studies on the registry are indexed under Depressive Disorder; 159 are open to participants now.
Browse Depressive Disorder studies →3 of the 14 studies in Depressive Disorder with a site in Sweden are open now. Recruiting first, the newest first:
Sahlgrenska University Hospital · Sites in Sweden
Ages 12+
Linkoeping University · Sites in Sweden
Ages 18+
Göteborg University · Sites in Sweden
Ages 25–75
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 67 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 3
First in 2004; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 349 is above the median of 88 across 689 interventional studies indexed under Depressive Disorder.
Median enrollment 158 across the 14 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
Göteborg University is the lead sponsor of 270 studies on the registry; 46 are open to participants now.
Göteborg University has 2 studies filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Depressive Disorder with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07637799Sahlgrenska University HospitalFeasibility Study of UP-A-AST Parent Group for Adolescents With Autism and Co-occurring Anxiety/Depression | 2026-12-30 |
| NCT03250026Göteborg UniversityCooperation for Primary Care Patients on Sick Leave for CMD: Care Manager and Workplace Intervention - CO-WORK-CARE | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Depressive Disorder with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate whether a convergence dialogue during sick leave, between the employee and the employer, with the Primary Care Centre Rehab Coordinator as discussion leader, leads to reduced sick leave time compared to those individuals who only have contact with a Care Manager during the period of sick leave. The study will be performed as a randomised controlled trial with randomisation at the PCC level where intervention PCCs offers a convergence dialogue meeting with the work place representative during sick leave in addition to Care Manager contact.
In Sweden sick leave time and frequency are increasing. This is primarily in the area of common mental disorders (CMD), and CMD is now the most common single cause of sickness absence. Primary care is the area in which most individuals with mental illness seek care and also receive care. A Care Manager function at the primary care centre (PCC) where the Care Manager is responsible for the support and close contact with patients with CMD and act as the "spider in the web" and combine patient support with other measures, have been shown to have beneficial effects for depression course. In Region Västra Götaland an implementation of the Care Manager function at the PCC has been set out, and the function is now available in nearly 100 PCCs in the region. The present study aims to evaluate whether a convergence dialogue during sick leave, between the employee and the employer, with the PCCs Rehab Coordinator as discussion leader, leads to reduced sick leave time compared to those individuals who only have contact with the Care Manager during the period of sick leave. The study will be performed as pragmatic randomised controlled trial with randomisation at the PCC level. Around 20 PCCs with a Care Manager function for patients on sick-leave with CMD diagnosis will be recruited and randomized to intervention where patients in addition to a Care Manager contact (12 weeks) will have one convergence dialogue meeting with the work place representative during sick leave. Control PCCs will give Care Manager contact 12 weeks only.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients attending primary care centers with care manager function
Exclusion Criteria:
Intervention: Work place convergence dialogue contact
Behavioral: Workplace convergence dialogue · Behavioral: Care Manager
Intervention: Care Manager contact 12 weeks (Care as usual)
Behavioral: Care Manager
Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide
Regular contact Care Manager during around 12 weeks
Net and gross sick-leave days
number of net and gross sick-leave days during 12 months
Time frame: 12 months
Depressive symptoms
Change of depressive symptoms Montgomery-Asberg Depression Rating Scale - Self rating version (MADRS-S) Range 0-60 (Total score) Low score better outcome
Time frame: 6 and 12 months
Anxiety symptoms
Change of anxiety symptoms Generalized Anxiety Disorder 7-item (GAD-7) scale Range 0-15 (total score) low score better outcome
Time frame: 6 and 12 months
Quality-of-life questionnaire score
Change of quality of life EuroQoL-5 Dimension Questionnaire(EQ-5D) Range 0-1.0(total score) low score worst outcome
Time frame: 6 and 12 months
Work ability
Change of work ability Work Ability Index (WAI) Range 7-49 (total score) low score worst outcome
Time frame: 6 and 12 months
Exhaustion
Change of Exhaustion Karolinska Exhaustion Disorder Scale (KEDS) Range 0-54 (total score) low score better outcome
Time frame: 6 and 12 months
Plan to share: Yes — De-identified data of individual participants will be made available to other researchers, provided reasonable request by personal contact, as soon as publication of results is effected.
Supporting information: Study protocol, Informed consent form, Clinical study report
Time frame: Data will be available after 12 months after study completion/ alternatively as soon as publication of results is effected.
Access criteria: Data access will be reviewed by an external independent review panel.
Started Dec 2017 (actual). Primary completion is estimated for Dec 2026, 108 months after the start.
Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 108 months is above that.
Counting every sponsor, half of 275 studies reached it within 29 months; a quarter within 15 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.